Friday, October 19, 2018

Luminex Acquires Flow Cytometry Assets From MilliporeSigma

Austin-based Luminex said Thursday that it has signed a definitive agreement to acquire the flow cytometry portfolio of MilliporeSigma, in a deal worth $75M. Luminex said the deal was split between $69.9M under a stock and asset purchase and approximately $5.1M in committed inventory purchases. Luminex said the deal will expand its flow-based detection systems offerings. MilliporeSigma's products are used for clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research among other areas. Luminex said it was advised by Cantor Fitzgerald & Co., along with Smith, Gambrell & Russell, LLP serving as legal counsel.